ORBIMED ADVISORS LLC Insider Trading $GKOS GLAUKOS Corp
Get free email notifications about insider trading for ORBIMED ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ORBIMED ADVISORS LLC. ORBIMED ADVISORS LLC is 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in GLAUKOS Corp ($GKOS) and Director in RESPONSE BIOMEDICAL CORP ($RPBIF) and Director in INTERCEPT PHARMACEUTICALS INC ($ICPT) and in ACCELERON PHARMA INC ($XLRN) and Director in ProNAi Therapeutics Inc ($DNAI) and 10% Owner in AVEDRO INC ($AVDR) and 10% Owner in Relypsa Inc ($RLYP) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ARPO) and Director in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and Director in SELECTA BIOSCIENCES INC ($SELB) and Director in SI-BONE, Inc. ($SIBN) and Director in Xtant Medical Holdings, Inc. ($XTNT) and 10% Owner in Roka BioScience, Inc. ($ROKA) and Director in Roka BioScience, Inc. ($ROKA) and 10% Owner in Kala Pharmaceuticals, Inc. ($KALA) and Director in Otonomy, Inc. ($OTIC) and 10% Owner in Arsanis, Inc. ($ASNS) and 10% Owner in Principia Biopharma Inc. ($PRNB) and Director in Acutus Medical, Inc. ($AFIB) and Director in SYNLOGIC, INC. ($MIRN) and 10% Owner in NeuroPace Inc ($NPCE) and 10% Owner in GRAYBUG VISION, INC. ($GRAY) and 10% Owner in Sientra, Inc. ($SIEN) and 10% Owner in TELA Bio, Inc. ($TELA) and Director in Loxo Oncology, Inc. ($LOXO) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Dimension Therapeutics, Inc. ($DMTX) and 10% Owner in Guardant Health, Inc. ($GH) and 10% Owner in ViewRay, Inc. ($VRAY) and Director in ViewRay, Inc. ($VRAY) and Director in Turning Point Therapeutics, Inc. ($TPTX) and in Tricida, Inc. ($TCDA) and Director in Tricida, Inc. ($TCDA) and 10% Owner in Inspire Medical Systems, Inc. ($INSP) and Director in Inspire Medical Systems, Inc. ($INSP) and Director in Synthorx, Inc. ($THOR) and 10% Owner in scPharmaceuticals Inc. ($SCPH) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in ALPINE IMMUNE SCIENCES, INC. ($NVLS) and Director in Corvus Pharmaceuticals, Inc. ($CRVS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and Director in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in Intellia Therapeutics, Inc. ($NTLA) and 10% Owner in Alector, Inc. ($ALEC) and Director in Alector, Inc. ($ALEC) and Director in Decibel Therapeutics, Inc. ($DBTX) and Director in NextCure, Inc. ($NXTC) and Director in LogicBio Therapeutics, Inc. ($LOGC) and Director in Silverback Therapeutics, Inc. ($SBTX) and Director in IMARA Inc. ($IMRA) and Director in Keros Therapeutics, Inc. ($KROS) and Director in Prelude Therapeutics Inc ($PRLD) and Director in PMV Pharmaceuticals, Inc. ($PMVP) and Director in ARMO BioSciences, Inc. ($ARMO) and Director in resTORbio, Inc. ($TORC) and Director in Prevail Therapeutics Inc. ($PRVL) and 10% Owner in SpringWorks Therapeutics, Inc. ($SWTX) and Director in Edgewise Therapeutics, Inc. ($EWTX) and Director in 89bio, Inc. ($ETNB) and Director in Arcutis Biotherapeutics, Inc. ($ARQT) and in Kinnate Biopharma Inc. ($KNTE) and Director in Oric Pharmaceuticals, Inc. ($ORIC) and Director in Repare Therapeutics Inc. ($RPTX) and Director in Fusion Pharmaceuticals Inc. ($FUSN) and Director in Terns Pharmaceuticals, Inc. ($TERN) and Director in Ikena Oncology, Inc. ($IKNA).
ORBIMED ADVISORS LLC in GLAUKOS Corp
Trading Symbol: GKOSIndustry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of ORBIMED ADVISORS LLC: Director
Holdings: 562,839 shares
Current Value: $24,950,653
Latest Transaction: Mar 06 2018
$GKOS Market Capitalization: $1.51B
$GKOS Previous Close: $44.33
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of ORBIMED ADVISORS LLC in GLAUKOS Corp
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, XLRN, AFIB, ADAP, TORC, AGLE, ARPO, ALEC, ALPN, ARQT, ARMO, BOLD, AVDR, CNST, CRVS, CTIC, DBTX, DMTX, EWTX, FUSN, GKOS, GRAY, GH, IKNA, IMRA, INSP, NTLA, ICPT, KALA, KROS, KNTE, LOGC, LOXO, NPCE, NXTC, ORIC, OTIC, PIRS, PMVP, PRLD, PRVL, PRNB, RLYP, RPTX, RPBIF, RYTM, SCPH, SELB, SIBN, SIEN, SRRA, SBTX, ROKA, SWTX, STDY, SYBX, THOR, TELA, TERN, TCDA, TPTX, VRAY, ASNS, XTNT
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.06 | 445 | 14,267 | 0 | 445 to 0 (-100.00 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.06 | 46,676 | 1,496,433 | 0 | 46.7 K to 0 (-100.00 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.77 | 192 | 5,908 | 445 | 637 to 445 (-30.14 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.77 | 20,114 | 618,908 | 46,676 | 66.8 K to 46.7 K (-30.12 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.01 | 886 | 26,589 | 637 | 1.5 K to 637 (-58.17 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.01 | 93,008 | 2,791,170 | 66,790 | 159.8 K to 66.8 K (-58.20 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.06 | 768 | 25,390 | 1,523 | 2.3 K to 1.5 K (-33.52 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.06 | 80,516 | 2,661,859 | 159,798 | 240.3 K to 159.8 K (-33.50 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.05 | 1,220 | 39,101 | 2,291 | 3.5 K to 2.3 K (-34.75 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.05 | 128,092 | 4,105,349 | 240,314 | 368.4 K to 240.3 K (-34.77 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.80 | 1,851 | 60,713 | 3,511 | 5.4 K to 3.5 K (-34.52 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 32.80 | 194,433 | 6,377,402 | 368,406 | 562.8 K to 368.4 K (-34.55 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 31.92 | 2,533 | 80,853 | 5,362 | 7.9 K to 5.4 K (-32.08 %) |
Mar 06 2018 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 31.92 | 265,766 | 8,483,251 | 562,839 | 828.6 K to 562.8 K (-32.07 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 40.77 | 553 | 22,546 | 7,895 | 8.4 K to 7.9 K (-6.55 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 40.77 | 58,047 | 2,366,576 | 828,605 | 886.7 K to 828.6 K (-6.55 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 39.63 | 1,808 | 71,651 | 8,448 | 10.3 K to 8.4 K (-17.63 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 39.63 | 189,792 | 7,521,457 | 886,652 | 1.1 M to 886.7 K (-17.63 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.94 | 1,651 | 62,639 | 10,256 | 11.9 K to 10.3 K (-13.87 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.94 | 173,349 | 6,576,861 | 1,076,444 | 1.2 M to 1.1 M (-13.87 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.72 | 1,038 | 39,153 | 11,907 | 12.9 K to 11.9 K (-8.02 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.72 | 109,040 | 4,112,989 | 1,249,793 | 1.4 M to 1.2 M (-8.02 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.82 | 424 | 16,036 | 12,945 | 13.4 K to 12.9 K (-3.17 %) |
Sep 05 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.82 | 44,498 | 1,682,914 | 1,358,833 | 1.4 M to 1.4 M (-3.17 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.85 | 2,140 | 80,999 | 13,369 | 15.5 K to 13.4 K (-13.80 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 37.85 | 224,780 | 8,507,923 | 1,403,331 | 1.6 M to 1.4 M (-13.81 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 38.01 | 619 | 23,528 | 15,509 | 16.1 K to 15.5 K (-3.84 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 38.01 | 64,961 | 2,469,168 | 1,628,111 | 1.7 M to 1.6 M (-3.84 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 38.29 | 307 | 11,755 | 16,128 | 16.4 K to 16.1 K (-1.87 %) |
Aug 17 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 38.29 | 32,193 | 1,232,670 | 1,693,072 | 1.7 M to 1.7 M (-1.87 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 44.54 | 699 | 31,133 | 16,435 | 17.1 K to 16.4 K (-4.08 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 44.54 | 73,401 | 3,269,281 | 1,725,265 | 1.8 M to 1.7 M (-4.08 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 46.13 | 7 | 323 | 17,134 | 17.1 K to 17.1 K (-0.04 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 46.13 | 693 | 31,968 | 1,798,666 | 1.8 M to 1.8 M (-0.04 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 45.30 | 1,998 | 90,509 | 17,141 | 19.1 K to 17.1 K (-10.44 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 45.30 | 208,712 | 9,454,654 | 1,799,359 | 2 M to 1.8 M (-10.39 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 45.98 | 915 | 42,072 | 19,129 | 20 K to 19.1 K (-4.56 %) |
Mar 14 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 45.98 | 96,113 | 4,419,276 | 2,008,071 | 2.1 M to 2 M (-4.57 %) |
Mar 07 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 47.05 | 526 | 24,748 | 20,044 | 20.6 K to 20 K (-2.56 %) |
Mar 07 2017 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 47.05 | 55,246 | 2,599,324 | 2,104,184 | 2.2 M to 2.1 M (-2.56 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.72 | 133 | 4,485 | 20,570 | 20.7 K to 20.6 K (-0.64 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.72 | 13,967 | 470,967 | 2,159,430 | 2.2 M to 2.2 M (-0.64 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.63 | 1,518 | 51,050 | 20,703 | 22.2 K to 20.7 K (-6.83 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.63 | 159,382 | 5,360,017 | 2,173,397 | 2.3 M to 2.2 M (-6.83 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.77 | 1,113 | 37,586 | 22,221 | 23.3 K to 22.2 K (-4.77 %) |
Aug 12 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 33.77 | 116,825 | 3,945,180 | 2,332,779 | 2.4 M to 2.3 M (-4.77 %) |
Aug 05 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.59 | 4,010 | 122,666 | 23,334 | 27.3 K to 23.3 K (-14.67 %) |
Aug 05 2016 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Sell | S | 30.59 | 420,990 | 12,878,084 | 2,449,604 | 2.9 M to 2.4 M (-14.67 %) |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 7.65 | 261 | 1,997 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 7.65 | 27,346 | 209,197 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 2,672 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 280,531 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 1,599 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 167,898 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 22,923 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 2,406,441 | 0 | 0 | |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Payment of Exercise | F | 18.00 | 111 | 1,998 | 27,344 | 27.5 K to 27.3 K (-0.40 %) |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 261 | 0 | 27,455 | 27.2 K to 27.5 K (+0.96 %) |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Payment of Exercise | F | 18.00 | 11,623 | 209,214 | 2,870,593 | 2.9 M to 2.9 M (-0.40 %) |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 27,346 | 0 | 2,882,216 | 2.9 M to 2.9 M (+0.96 %) |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 27,194 | 0 | 27,194 | 0 to 27.2 K |
Jun 30 2015 | GKOS | GLAUKOS Corp | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 2,854,870 | 0 | 2,854,870 | 0 to 2.9 M |
Page: 1